Literature DB >> 6433981

Studies on haptoglobin binding to concanavalin A.

I Katnik.   

Abstract

Ascitic fluid haptoglobins 1-1, 2-1 and 2-2 and their tryptic glycopeptides were fractionated by affinity chromatography on Con A-Sepharose. Three peaks were obtained, corresponding to non-binding, weakly binding and strongly binding fractions. Concanavalin A-non-binding and concanavalin A-binding fractions of haptoglobin and of glycopeptide III 2-2 consisted of a series of polymers with increasing molecular mass, except for the non-binding fraction of glycopeptide III 1-1. After reduction there was no difference between the subunit composition of the glycopeptides and their concanavalin A fraction. Concanavalin A-non-binding fractions from haptoglobin 2-1 and glycopeptides III 1-1 and III 2-2 did not form an active complex with hemoglobin and, in crossed immunodiffusion, showed a reaction of partial identity with haptoglobin 2-1, glycopeptides III 1-1, III 2-2 and their concanavalin A-binding fractions. Concanavalin A-binding fractions of the above preparations exhibited with hemoglobin higher peroxidase activity than before their separation on Con A-Sepharose and immunodiffusion gave a reaction of identity among themselves and with unfractionated preparations. The concanavalin A-binding glycopeptide III is the biologically active part of the haptoglobin beta-chain.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6433981     DOI: 10.1016/0167-4838(84)90325-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

Review 1.  Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms.

Authors:  G A Turner; M T Goodarzi; S Thompson
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

2.  Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes.

Authors:  Nishant M Bhensdadia; Kelly J Hunt; Maria F Lopes-Virella; J Michael Tucker; Mohammad R Mataria; Joseph L Alge; Benjamin A Neely; Michael G Janech; John M Arthur
Journal:  Kidney Int       Date:  2013-03-27       Impact factor: 10.612

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.